As of December 23, 2025, ProMIS Neurosciences, Inc. had a $17.5 million market capitalization, putting it in the 9th percentile of companies in the Biotechnology industry. ProMIS Neurosciences, Inc.
Bun 1.3 revolutionizes full-stack JavaScript development with unified database APIs and zero-config frontend setup.
Prediction markets are growing quickly in the United States. Here's what you need to know about them and how they affect the ...
The selling point for the No. 17 pick in the 2024 draft has always been potential and it appears he's starting to live up to ...
At the core of every AI coding agent is a technology called a large language model (LLM), which is a type of neural network ...
As the Twins approach what could be a fascinating Spring Training, much of the prospect hype surrounds their young hitters.
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody ...
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback